Intra-cranial efficacy of brigatinib in an ALK-positive non-small cell lung cancer patient presenting leptomeningeal carcinomatosis

Survivals of advanced anaplastic lymphoma kinase (ALK –positive) non-small cell lung cancer (NSCLC) patients have dramatically changed since the development of efficient ALK tyrosine kinase inhibitors (TKi). However, ALK-positive patients seem to relapse more commonly in the central nervous system (CNS), considered as a sanctuary site. Whether brain metastases (BM) or lepto-meningeal disease (LMD), both are associated with very poor prognosis [1]. Though there is evidence of intracranial activity of 1st generation ALK TKi - crizontib to 2nd and next-generations TKi alectinib, ceretinib against BM, few cases report their activity on LMD.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research